Answers are grounded in this paper and cite their sources.
May inform ultrasound steatosis assessment in MASLD; leaves open prospective validation before routine adoption.
L. Xue, Y. Zhu, H. Xu, and H. Ding, “Chinese Expert Consensus on the Use of Ultrasound-Derived Fat Fraction in the Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease (2025 Edition),” Portal Hypertension & Cirrhosis5 (2026): 1-16. https://doi.org/10.1002/poh2.70042. In the “Ethics Statement” section, the text “The authors have nothing to report.” should be changed as “This consensus is a translated version of the previously published Chinese-language consensus “Chinese expert consensus on the use of ultrasound derived fat fraction in the assessment of metabolic dysfunction-associated steatotic liver disease (2025 edition).” published in Chinese Journal of Ultrasonography, 2025, 34(12): 1033-1045. DOI:10.3760/cma.j.cn131148-20251009-00541. All procedures performed in this consensus involving human participants were in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Huashan Hospital, Fudan University (2023-056). Written informed consent was obtained from all patients.” We apologize for this error.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied Metabolic Dysfunction-Associated Steatotic Liver Disease. Ultrasound-Derived Fat Fraction was evaluated. A correction was issued to update the ethics statement for the Chinese Expert Consensus on ultrasound-derived fat fraction in metabolic dysfunction-associated steatotic liver disease.
Synapse has enriched 10 related papers. Consider them for comparative context: